![](https://ml.globenewswire.com/media/babbb6b5-0b4f-4682-8553-c4dc6481ed59/small/sermonix-new-logo-jpeg-2-jpg.jpg)
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast ...
COLUMBUS, Ohio and SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), and Quantum Leap …